The DOI matches its Crossref record.
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Open accessAbstract
Background: Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy. Methods: Data from two phase III clinical trials of omalizumab in patients with allergic asthma were examined. Differences in rates of asthma exacerbations between omalizumab and placebo groups during the 16‐week inhaled corticosteroid (ICS) dose‐stable phase were evaluated with respect to baseline blood eosinophil counts (eosinophils <300/μL [low] vs ≥300/μL [high]) and baseline markers of asthma severity (emergency asthma treatment in prior year, asthma hospitalization in prior year, forced expiratory volume in 1 second [FEV1; FEV1 <65% vs ≥65% predicted], inhaled beclomethasone dipropionate dose [<600 vs ≥600 μg/day], and long‐acting beta‐agonist [LABA] use [yes/no]). Results: Adults/adolescents (N = 1071) were randomized to receive either omalizumab (n = 542) or placebo (n = 529). In the 16‐week ICS dose‐stable phase, rates of exacerbations requiring ≥3 days of systemic corticosteroid treatment were 0.066 and 0.147 with omalizumab and placebo, respectively, representing a relative rate reduction in omalizumab‐treated patients of 55% (95% CI, 32%‐70%; P = .002). For patients with eosinophils ≥300/μL or with more severe asthma, this rate reduction was significantly more pronounced. Conclusion: In patients with allergic asthma, baseline blood eosinophil levels and/or clinical markers of asthma severity predict response to omalizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
Agache, I., Beltran, J., Akdis, C., Akdis, M., Canelo‐Aybar, C., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Del Giacco, S., et al. (2020) · Allergy · doi:10.1111/all.14221 · Cited by 408
Self-citationCharacterization of Severe Asthma Worldwide
Wang, E., Wechsler, M. E., Tran, T. N., Heaney, L. G., Jones, R. C., Menzies-Gow, A. N., Busby, J., Jackson, D. J., Pfeffer, P. E., Rhee, C. K., et al. (2020) · Chest · doi:10.1016/j.chest.2019.10.053 · Cited by 351
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Kelsen, S. G., Agache, I. O., Soong, W., Israel, E., Chupp, G. L., Cheung, D. S., Theess, W., Yang, X., Staton, T. L., Choy, D. F., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.044 · Cited by 319
Casale, T. B., Luskin, A. T., Busse, W., Zeiger, R. S., Trzaskoma, B., Yang, M., Griffin, N. M., & Chipps, B. E. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.04.043 · Cited by 276
Self-citation
Metadata
- Authors
- Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., & Hanania, N. A.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2017-09-23
- Volume
- 73
- Issue
- 2
- Pages
- 490-497
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2750584686
- Cited by
- 158
- References
- 0
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. https://app.cochat.ai/papers/10.1111/all.13302
- The paper
- Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., & Hanania, N. A. (2018). Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. https://doi.org/10.1111/all.13302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.